← Zhuhai Rundu Pharmaceutical overview

Zhuhai Rundu Pharmaceutical vs Zhejiang Huahai Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Zhuhai Rundu Pharmaceutical Co Ltd Class A (002923.CS)

Q3 2026
▲2▼1

Rundu swings to profit as new heart drugs win approvals

  • New hypertension drug approvals widen product line Rundu won Chinese approval for azilsartan tablets and, separately, marketing approval for amlodipine besylate, the key ingredient in a common blood-pressure medicine. Both add to its heart and stroke product range, supporting future sales and its ingredient-to-finished-pill chain.

    These regulatory approvals are genuinely new and expand the products the company can sell.

  • Innovative heart-imaging drug gets provincial support Rundu's first-in-class higenamine hydrochloride injection was picked for Guangdong's innovative drug catalog. That status brings provincial policy support for promoting and selling the product, which should help it reach more hospitals and patients over time.

    This is a new regulatory win that could lift sales of a high-value innovative product.

  • Controlling shareholder still heavily pledged Controlling shareholder Li Xi released 2.15 million pledged shares, but 97.2% of his stake remains pledged. Heavy pledging can signal personal financial strain and, if shares fall, risks forced selling that would weigh on the stock price.

    This is the main counterweight to the good news and a real risk investors should weigh.

August 2026
▲2▼1

Rundu swings to profit as new heart drugs win approvals

  • New hypertension drug approvals widen product line Rundu won Chinese approval for azilsartan tablets and, separately, marketing approval for amlodipine besylate, the key ingredient in a common blood-pressure medicine. Both add to its heart and stroke product range, supporting future sales and its ingredient-to-finished-pill chain.

    These regulatory approvals are genuinely new and expand the products the company can sell.

  • Innovative heart-imaging drug gets provincial support Rundu's first-in-class higenamine hydrochloride injection was picked for Guangdong's innovative drug catalog. That status brings provincial policy support for promoting and selling the product, which should help it reach more hospitals and patients over time.

    This is a new regulatory win that could lift sales of a high-value innovative product.

  • Controlling shareholder still heavily pledged Controlling shareholder Li Xi released 2.15 million pledged shares, but 97.2% of his stake remains pledged. Heavy pledging can signal personal financial strain and, if shares fall, risks forced selling that would weigh on the stock price.

    This is the main counterweight to the good news and a real risk investors should weigh.

Latest
▲2▼1

Rundu swings to profit as new heart drugs win approvals

  • New hypertension drug approvals widen product line Rundu won Chinese approval for azilsartan tablets and, separately, marketing approval for amlodipine besylate, the key ingredient in a common blood-pressure medicine. Both add to its heart and stroke product range, supporting future sales and its ingredient-to-finished-pill chain.

    These regulatory approvals are genuinely new and expand the products the company can sell.

  • Innovative heart-imaging drug gets provincial support Rundu's first-in-class higenamine hydrochloride injection was picked for Guangdong's innovative drug catalog. That status brings provincial policy support for promoting and selling the product, which should help it reach more hospitals and patients over time.

    This is a new regulatory win that could lift sales of a high-value innovative product.

  • Controlling shareholder still heavily pledged Controlling shareholder Li Xi released 2.15 million pledged shares, but 97.2% of his stake remains pledged. Heavy pledging can signal personal financial strain and, if shares fall, risks forced selling that would weigh on the stock price.

    This is the main counterweight to the good news and a real risk investors should weigh.

Zhejiang Huahai Pharmaceutical Co Ltd (600521.CG)

Q3 2026
▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

  • Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.

    This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.

  • Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.

    A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.

  • Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.

    Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.

  • US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.

    These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.

August 2026
▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

  • Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.

    This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.

  • Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.

    A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.

  • Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.

    Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.

  • US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.

    These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.

Latest
▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

  • Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.

    This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.

  • Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.

    A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.

  • Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.

    Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.

  • US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.

    These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.